Aurora Kinase inhibitor MK-0457 inhbits Ovarian Cancer Growth in mouse model

MK-0457 significantly reduced the proliferation of ovarian cancer cells, alone and in combination with docetaxel, in an orthotopic mouse model

ImClone submit sBLA for Erbitux in First-Line Head and Neck Cancer

ImClone Systems has submitted an sBLA to the US FDA to broaden the use of ERBITUX (cetuximab) to include first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Vandetanib effective in xenograft models of sarcoma

AstraZeneca’s VEGFR2/EGFR inhibitor has shown activity against sarcoma cell lines in xenograft models

Plexxicon initiate Phase I trial with kinase inhibitor in Pain and Polycystic Kidney Disease

Plexxicon have initiated a Phase I trial with a kinase inhibitor in Pain and Polycystic Kidney Disease. The target has not been disclosed

University of Tübingen publish series of p38 MAP kinase inhibitors

Researchers from the University of Tübingen have published a series of p38 MAP kinase inhibitors

Abstract:
\

BMS publish discovery of IGF-R1 inhibitor BMS-695735

BMS have published data on the discovery of IGF-R1 inhibitor BMS-695735

Wyeths EKB-569 safe in Phase I trials in Colorectal Cancer

Phase I data show Wyeths EGFR/HER2 inhibitor EKB-569 to be safe in colorectal cancer patients when administered in combination with capecitabine

Caliper Life Sciences launch RapidKinase, Mechanism of Action Studies and >200 kinase assays

Caliper Life Sciences have launched RapidKinase™ profiling and enzymatic Mechanism of Action™ studies.The RapidKinase service utilizes the LabChip® EZ Reader™ and ProfilerPro™ reagent. Mechanism of Action studies provide researchers with information on how their compounds interact with enzymatic targets.
In addition they have launched >200 kinase profiling ready to use assays

Amgen publish series of amido-benzisoxazole c-Kit inhibitors

Amgen have published a series of c-Kit inhbitors

Amgen publish series of c-Met inhibitors

Amgen have published a series of c-Met inhbitors